In drug therapy, identifying whether a patient is a fast acetylator can help tailor personalized medicine strategies. For drugs that are metabolized by acetylation, fast acetylators might experience reduced therapeutic effects, necessitating dosage adjustments. Conversely, some drugs might become toxic if metabolized too quickly, so understanding an individual's acetylation status can prevent potential drug toxicity. A classic example is the drug isoniazid, used for tuberculosis treatment, which can be cleared from the body more rapidly in fast acetylators, affecting its efficacy.
